SLC5A2 and chronic kidney disease: Notably, DAPA-CKD was also the only trial to show a clear benefit of SGLT-2 inhibition on survival since the risk for all-cause death was 31% lower in the dapagliflozin group than in the placebo group (HR: 0.69; 95% CI: 0.53–0.88) [20].